ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RGNT
CLGN (41) CUPR (21) HSCS (38) LFWD (32) ⌘ Pro Terminal →

Regentis Biomaterials Ltd. (RGNT) — RQD Stock Rating Cockpit

$1.37 0.00% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.37

Regentis Biomaterials Ltd. (RGNT) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $9.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RGNT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RGNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Regentis Biomaterials Ltd. (NYSE: RGNT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.37 (0.00% 1D, market cap $9.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RGNT ranks #777 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RGNT compare to CLGN and CUPR in the Health Care sector?
▼

Within the Health Care sector (Industrial Specialties), RGNT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, RGNT leads on earnings multiple (N/A) while RGNT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RGNT?
▼

Per RGNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001912966), Regentis Biomaterials Ltd. generated $19.5M in revenue (+647.6% YoY), -$13.6M in net income, and -$1.4M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.37 (-0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (3)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.4% Base Target
$16 Bull$1 Base$1 Bear
📬 FREE RGNT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RGNT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY RGNT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$1.63-9.8% Next Q
Q2 (-2Q)
36
Grade E$1.47-12.2% Next Q
Q3 (-1Q)
34
Grade E$1.29+6.2% Next Q
Current
31
Grade E$1.37-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RGNT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RGNT currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.75) and Max Pain ($1.44) forces dealer call-delta covering toward $16.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RGNT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RGNT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
38.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$1.37H: $16
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 17 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on RGNT

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and -14.39% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

6/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like RGNT
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RGNT)

  • ✓Walkthrough of RGNT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RGNT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.27%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.36H $1.37L $1.36C $1.37VOL 24.9K
RES: $2.68SUP: $1.20SMA50: $1.75SMA200: $2.86
$16.50$12.36$8.22$4.08$-0.05RES $2.68SUP $1.20$1.372026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RGNT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RGNT Butterfly Map → + Track RGNT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +647.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RGNT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RGNT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RGNT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RGNT)

Health Care Rank #777 of 1015 ⚔️ CLGN vs RGNT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RGNT vs. CLGN, CUPR, HSCS, LFWD)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Regentis Biomaterials Ltd. (RGNT) ranks #777 by composite RQD confidence (31/100, grade E) and #896 by equity capitalization ($9.6M). Within this direct 5-issuer industry benchmark cohort, RGNT leads on earnings valuation at N/A trailing P/E, while RGNT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with RGNT at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RGNT ACTIVE
Regentis Biomaterials Ltd.
E 31/100 — — -35.0% 0.00% $9.6M Benchmark Subject
CLGN
CollPlant Biotechnologies Ltd
D- 41/100 — 64.8% -35.0% -1.33% $11.9M /clgn-vs-rgnt →
CUPR
Cuprina Holdings (Cayman) Limited (Class A)
E 21/100 — -1.3% -35.0% +3.96% $13.5M /cupr-vs-rgnt →
HSCS
HeartSciences Inc.
D- 38/100 — 59.1% -35.0% -9.67% $16.0M /hscs-vs-rgnt →
LFWD
Lifeward Ltd.
E 32/100 — 96.0% -35.0% +1.82% $16.9M /lfwd-vs-rgnt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001912966 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Regentis Biomaterials Ltd. (RGNT) reported GAAP revenue of $19.5M (+647.6% vs. FY2024 revenue of $2.6M , and +260.8% cumulative change since FY2023) , GAAP net income of -$13.6M, operating cash flow of -$1.4M, and free cash flow of -$1.4M (-114.5% YoY). On the balance sheet, RGNT closed FY2025 with $7.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $19.5M -$13.6M -$1.4M -$1.4M $7.6M —
FY2024 (FY) 2024-12-31 $2.6M $4.8M -$641.0K -$641.0K $482.0K —
FY2023 (FY) 2023-12-31 $5.4M -$4.1M -$1.2M -$1.2M — —

3. RGNT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RGNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Regentis Biomaterials Ltd. (NYSE: RGNT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.37 (0.00% 1D, market cap $9.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RGNT ranks #777 in composite RQD confidence.

How does RGNT compare to CLGN and CUPR in the Health Care sector?

Within the Health Care sector (Industrial Specialties), RGNT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, RGNT leads on earnings multiple (N/A) while RGNT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RGNT?

Per RGNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001912966), Regentis Biomaterials Ltd. generated $19.5M in revenue (+647.6% YoY), -$13.6M in net income, and -$1.4M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RGNT trading relative to its 50-day, 200-day, and 52-week technical levels?

RGNT last traded at $1.37 (0.00% on volume of 15,303 shares), positioning the stock -21.71% below its 50-day simple moving average ($1.75) and -52.10% below its 200-day simple moving average ($2.86). Across its 52-week range of $1.23 to $15.50, RGNT sits at the 1.0% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.20 to $1.54).

Direct Sub-Reports: RGNT RQD Cockpit RGNT 12M Forecast RGNT Earnings & Move RGNT Dividends & DRIP RGNT Insiders & 13F RGNT Whale Options RGNT Profit Sankey RGNT News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

RGNT — Regentis Biomaterials Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Regentis Biomaterials Ltd. (RGNT) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.37 (0.00% 1D, market capitalization $9.6M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -14.39%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Regentis Biomaterials Ltd. (RGNT) is a NYSE-listed issuer classified in the Health Care sector and the Industrial Specialties industry. Reported revenue is — in each period shown in the SEC financials, so the source does not establish how the company generates income. Market capitalization is listed as $9.6M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Regentis Biomaterials Ltd. (RGNT) reported $19.5M in annual revenue (up from $2.6M in FY2024, +647.6% YoY) and -$13.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.4M revenue, -$4.1M net income) through FY2025, RGNT scaled operating cash flow to -$1.4M and free cash flow to -$1.4M, backed by $7.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -14.39% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.23 – $15.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream suppliers, downstream customers, or sector correlations are identified in the source data. A prospective investor should therefore note that second-order ripple effects cannot be mapped from the available sources; any sector read-through would require information not present here.

  • Key Question #1: Can RGNT sustain or expand its — operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $19.5M and free cash flow of -$1.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is RGNT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RGNT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Regentis Biomaterials Ltd. (RGNT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RGNT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RGNT Bull vs. Bear Conversation Board — What's Your Call at $1.37?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RGNT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RGNT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $1.59 (+16.1%)
📌 Pinned Debate

Surgeon interest in GelrinC reported at the 8th ICRS Summit gives a possible commercial catalyst, and FY 2024 showed positive net incom

Picked up a starter position in RGNT in my $100K Virtual Cash book at $1.37. Surgeon interest in GelrinC reported at the 8th ICRS Summit gives a possible commercial catalyst, and FY 2024 showed positive net income of $4.8M.. Trading inside a $1.23–$15.50 52-week range with -14.39% FCF yield gives solid downside support if Industrial Specialties multiples expand this quarter.

SectorRotator 🐂 BULL

@DeltaGamma_99 Agree on the RQD 31/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.37 and keeping dry powder in case we test $1.27.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.08 (-21.2%)
Spot @ $1.37

ROIC of -35%, FCF yield of -14.39%, and an FY 2025 net loss of -$13.6M with a Piotroski F-Score of 1/9 point to weakening fundamentals.

ROIC of -35%, FCF yield of -14.39%, and an FY 2025 net loss of -$13.6M with a Piotroski F-Score of 1/9 point to weakening fundamentals.. Look at the math on RGNT: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Industrial Specialties demand softens. I'd wait for a retest of $1.21 before getting long.

LIVE TAPE